William Blair Has Bullish Forecast for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at William Blair increased their Q2 2025 EPS estimates for Vertex Pharmaceuticals in a research note issued to investors on Monday, July 14th. William Blair analyst M. Minter now expects that the pharmaceutical company will post earnings per share of $4.00 for the quarter, up from their previous estimate of $3.95. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the firm posted $4.76 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on the stock. Scotiabank dropped their price target on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a research note on Tuesday, May 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Morgan Stanley cut their price target on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an “equal weight” rating on the stock in a report on Friday, June 20th. Leerink Partnrs lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $511.71.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $469.55 on Tuesday. The business has a fifty day moving average price of $448.13 and a 200-day moving average price of $461.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The company has a market capitalization of $120.58 billion, a PE ratio of -119.78 and a beta of 0.41. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of large investors have recently made changes to their positions in VRTX. ORG Partners LLC grew its holdings in Vertex Pharmaceuticals by 17.4% during the second quarter. ORG Partners LLC now owns 250 shares of the pharmaceutical company’s stock valued at $113,000 after purchasing an additional 37 shares during the period. Ipswich Investment Management Co. Inc. grew its stake in shares of Vertex Pharmaceuticals by 1.6% during the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 5,608 shares of the pharmaceutical company’s stock valued at $2,497,000 after acquiring an additional 90 shares during the period. Vision Capital Management Inc. increased its holdings in Vertex Pharmaceuticals by 4.7% in the 2nd quarter. Vision Capital Management Inc. now owns 6,872 shares of the pharmaceutical company’s stock worth $3,059,000 after acquiring an additional 307 shares in the last quarter. American National Bank & Trust raised its stake in Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 67 shares during the period. Finally, Banque Pictet & Cie SA lifted its holdings in Vertex Pharmaceuticals by 48.9% during the second quarter. Banque Pictet & Cie SA now owns 16,937 shares of the pharmaceutical company’s stock valued at $7,540,000 after purchasing an additional 5,564 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.